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p53 Serine-15 phosphorylation
Ashley L Craig†1, Jitka Holcakova†2, Lee E Finlan1, Marta Nekulova2, Roman Hrstka2, Nuri Gueven3, James DiRenzo4, 
Graeme Smith5, Ted R Hupp1 and Borivoj Vojtesek*2
Abstract
Background: ΔNp63α is an epithelial progenitor cell marker that maintains epidermal stem cell self-renewal capacity. 
Previous studies revealed that UV-damage induced p53 phosphorylation is confined to ΔNp63α-positive cells in the 
basal layer of human epithelium.
Results: We now report that phosphorylation of the p53 tumour suppressor is positively regulated by ΔNp63α in 
immortalised human keratinocytes. ΔNp63α depletion by RNAi reduces steady-state ATM mRNA and protein levels, 
and attenuates p53 Serine-15 phosphorylation. Conversely, ectopic expression of ΔNp63α in p63-null tumour cells 
stimulates ATM transcription and p53 Serine-15 phosphorylation. We show that ATM is a direct ΔNp63α transcriptional 
target and that the ΔNp63α response element localizes to the ATM promoter CCAAT sequence. Structure-function 
analysis revealed that the ΔNp63-specific TA2 transactivation domain mediates ATM transcription in coordination with 
the DNA binding and SAM domains.
Conclusions: Germline p63 point mutations are associated with a range of ectodermal developmental disorders, and 
targeted p63 deletion in the skin causes premature ageing. The ΔNp63α-ATM-p53 damage-response pathway may 
therefore function in epithelial development, carcinogenesis and the ageing processes.
Background
p63 is the founding member of the p53 protein family,
and is required for the development of limbs and epithe-
lial structures in vertebrates [1]. The p63 gene expresses
at least 6 common transcripts by utilising two distinct
promoters (TA and ΔN) and alternative splicing within
the 3' end of mRNA that generates α,β and γ isoforms [2].
TAp63 variants contain a p53-like TA1 transactivation
domain. ΔNp63 variants lack a TA1 domain, but instead
contain a unique 14 amino acid sequence that contributes
to the formation of an alternative TA2 transactivation
domain [3]. All p63 variants contain a DNA-binding
domain and a tetramerisation domain with homology to
p53. However, p63 alpha isoforms encode a C-terminal
extension containing a SAM protein interaction domain,
a conserved functional element found in a range of devel-
opmental proteins [4].
Initial studies identified p63 as a robust biomarker for
epithelial progenitor, or stem, cells [5]. However, the
development of TA- and ΔN-isotype specific reagents
revealed that ΔNp63 expression is confined to the basal
layer of stratified squamous epithelium, whereas TAp63
variants predominate in suprabasal layers [6]. Similarly, in
vitro keratinocyte differentiation induces hypoexpression
of the predominant ΔNp63α isoform [7]. TAp63 isotypes
can transcriptionally activate a subset of p53 target genes
involved in cell cycle checkpoint control and apoptosis
[8,9]. In contrast, initial reports suggested that ΔNp63
variants had no intrinsic transcriptional activity, but
could antagonise TAp63- and p53-dependent target gene
transcription [2]. However, recent microarray-based
screening approaches have identified the transcriptional
targets of distinct p63 isotypes in tumour cells and in
immortalised keratinocytes [10]. These studies have
revealed that ΔNp63α can either activate or repress the
transcription of many target genes involved in multiple
cellular processes. The challenge now is to dissect how
specific validated ΔNp63α transcriptional targets medi-
ate ΔNp63α physiological function. For instance, loss of
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Page 2 of 13ΔNp63α-dependent transcriptional repression of
S100A2, p21WAF1 and 14-3-3 correlates with ΔNp63α
downregulation during keratinocyte differentiation
[7,11].
Our previous studies revealed that UV damage-induced
p53 phosphorylation is restricted to the ΔNp63α-positive
basal epidermal layer of UV-damaged human skin [12],
which provided an opportunity to identify novel physio-
logical regulators of the p53 damage response. Site-spe-
cific p53 phosphorylation has already been established to
play an important role in regulating the p53 response to
UV-damage. For example, p53 mutation at the conserved
UV-inducible CK2-site sensitizes mice to UV-induced
skin cancer and attenuates the p53 transcription pro-
gramme in MEFs [13]. In this study we show that a posi-
tive association between UV-induced p53
phosphorylation in ΔNp63α-positive immortalised kera-
tinocytes is explained by ΔNp63α-dependent transcrip-
tional control of the ATM kinase.
Results
The ATM kinase mediates p53 Serine-15 phosphorylation 
in immortalised keratinocytes
We previously reported the striking restriction of UV-
damage induced p53 site-specific phosphorylation to
ΔNp63α-positive epithelial progenitor cells in human
skin after UV irradiation in vivo. We have now used
ΔNp63α-positive/mutant p53 HaCat immortalised kera-
tinocytes [14] as a model system to investigate a potential
functional relationship between ΔNp63α and p53 phos-
phorylation. In this system, basal mutant p53 protein and
Serine-392 phosphorylation levels are high and not fur-
ther stabilised by DNA damage (Figure 1A). In contrast,
p53 Serine-15 phosphorylation is low, but is induced fol-
lowing UV-irradiation or treatment with the ATM path-
way activator, doxorubicin [15] (Figure 1A, lanes 2 and 3
vs. lane 1). Doxorubicin-induced Serine-15 phosphoryla-
tion is attenuated by the small molecule ATM inhibitor,
KU-55933 [16] (Figure 1A, lane 2 vs. lane 4), but is unaf-
fected by DNA-PK inhibition. These data confirm that
damage-activated ATM signaling functions normally in
ΔNp63α-positive HaCat cells. Following increased pro-
tein loading or exposure times, basal p53 Serine-15 phos-
phorylation was easily detectable and was also sensitive
to ATM inhibition (Figure 1B, lane 2 vs. lane 1) and
insensitive to DNA-PK inhibition. Other key ATM signal-
ing pathway components, including Chk2 Threonine-68
and ATM Serine-1981, are also constitutively phosphory-
lated (Figure 1C). Treatment with ATM siRNA attenu-
ated both ATM protein expression and p53 Serine-15
phosphorylation (Figure 1D), without affecting p53 levels
in comparison with control siRNA. These data confirm
that the ATM signaling pathway is primed for damage-
activation in ΔNp63α-positive HaCat cells, providing a
suitable model system to investigate a potential relation-
ship between ΔNp63α and ATM-dependent p53 phos-
phorylation.
ΔNp63α controls ATM expression and ATM-dependent 
phosphorylation
We next used two different methods to inhibit p63
expression, and determined their effects on ATM expres-
sion and ATM-dependent basal and damage-induced
phosphorylation. Firstly, transfection of HaCat cells with
the pSUPER-p63si expression plasmid [17] reduced
ΔNp63α mRNA (Figure 2A) and protein expression levels
Figure 1 The ATM pathway is active in HaCaT cells. (A) Damage-in-
duced p53 Serine-15 is mediated by ATM. HaCat cells were treated 
with DMSO carrier, 10 μM KU-55933 (ATM inhibitor) or 1 μM NU7441 
(DNA-PK inhibitor) for 2 hours, then with 0.5 μM doxorubicin, and cells 
were harvested after 2hrs, or cells were treated with 20Jm2 UV radiation 
and harvested after 6hrs. Lysates were blotted for phosphoSerine-15 
p53, phosphoSerine-392 p53, total p53 protein and p63, as indicated. 
(B) ATM inhibition blocks constitutive p53 Serine-15 phosphorylation. 
Cells were treated with DMSO carrier, 10 μM KU-55933 (ATM inhibitor) 
or 1 μM NU7441 (DNA-PK inhibitor) for 24 hrs, and lysates were immu-
noblotted for phosphoSerine-15 p53 and total p53 protein. (C) ATM in-
hibition blocks constitutive ATM-dependent phosphorylation. Cells 
were treated with DMSO carrier or 10 μM KU-55933 for 24 hrs, and 
lysates were immunoblotted for: phosphoSerine-15 p53, phosphoSer-
ine-392 p53, total p53 protein, phosphoThreonine-68 Chk2, total Chk2 
protein, phosphoSerine-1891 ATM, and total ATM protein. (D) siRNA-
mediated ATM depletion blocks p53 Serine-15 phosphorylation. HaCat 
cells were treated with control siRNA or siRNA to ATM for 24, 48 or 
96hrs, and cell lysates were blotted for ATM, phosphoSerine-15 p53, 
and total p53 protein.
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Figure 2 p63 depletion attenuates ATM expression and ATM-dependent phosphorylation. (A) pSUPER-p63 RNAi attenuates ATM mRNA levels. 
HaCat cells were transfected with 1 μg pSUPER-CON or pSUPER-p63si vectors, and selected for geneticin resistance for 4 days. mRNA was extracted 
from surviving cells and real-time RT-PCR was used to quantitate changes in ATM mRNA expression. Data is represented as fold-change over empty 
vector control. (B) pSUPER-p63si inhibits ATM expression and p53 Serine-15 phosphorylation in HaCat cells. pSUPER-CON or pSUPER-p63si transfected 
HaCat cells were harvested after selection for 48 and 96 hours, and immunoblotted for the indicated proteins. (C) pSUPER-p63 RNAi inhibits HaCat cell 
proliferation. HaCaT cells were transfected with pSUPER-CON or pSUPER-p63si vectors, selected for geneticin resistance for 14 days, and surviving col-
onies were giemsa stained and counted. (D) siRNA-mediated p63 depletion attenuates ATM mRNA expression. HaCat cells untreated (NT) or treated 
with control siRNA or p63-targeted siRNA were harvested after 24 hrs or 48hrs and analysed by real-time RT-PCR for p63 and ATM mRNA expression. 
Data is normalised to β-actin and represented as fold-change over mRNA level in cells treated with control siRNA in particular time point. The data 
represent the average of three independent experiments + SD. The symbol asterisk denotes significant difference with p values < 0.05 determined by 
Mann-Whitney test, from the cells treated with control siRNA.
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Page 4 of 13(Figure 2B). Depletion of ΔNp63α protein correlated with
reduced ATM protein expression and basal p53 Serine-15
phosphorylation in contrast with transfection of the pSU-
PER-CON plasmid (Figure 2B). These data suggest that
ΔNp63α-mediated control of ATM levels regulates ATM-
dependent p53 phosphorylation. Consistent with a role
for ΔNp63α in epithelial stem cell maintenance [18],
RNAi-mediated p63 depletion reduced colony survival
(Figure 2C). Secondly, treatment with p63-directed
siRNA oligonucleotides depleted ΔNp63α mRNA levels
after 24 hours and ATM mRNA levels were reduced after
48 hours (Figure 2D). These effects on ATM mRNA
occurring at later timepoints than downregulation of p63
mRNA is consistent with an ATM regulatory role for
ΔNp63α.
ΔNp63α controls phosphorylation of overexpressed p53
We next used p63 overexpression in the p53-deficient
and p63-deficient non-epithelial cell lines to (i) investi-
gate whether ΔNp63α-dependent ATM regulation could
be reconstituted and if so, (ii) to perform structure-func-
tion analyses to delineate the molecular mechanisms
involved.
In line with previous reports, overexpression of p63
variants TAp63α, TAp63γ, ΔNp63α and ΔNp63γ was
growth inhibitory (Figure 3A) [19]. TAp63 α and γ over-
expression strongly suppressed colony formation (Figure
3A) and correlated with expression of the p53 target and
CDK inhibitor, p21WAF1 (Figure 3C), whilst ΔNp63 iso-
forms did not induce p21WAF1 and only weakly sup-
pressed cell growth. Coexpression of ΔNp63α and
ΔNp63γ with p53 specifically increased p53 Serine-15
phosphorylation and expression of the TAp63 isoforms
had very weak or no effect on p53 phosphorylation (Fig-
ure 3B). Similarly, basal Threonine-68 phosphorylation of
exogenous Chk2 was high, but was also specifically stim-
ulated by ΔNp63α coexpression (data not shown). The
presence of multiple p63 bands is likely due to cleavage of
the full-length isoforms. As reported previously, we
noted that TAp63γ protein is less stable than other p63
isoforms, (Figures 3B, C) [2,20].
ΔNp63 isotypes stimulate the ATM promoter
ΔNp63α-mediated regulation of the ATM pathway may
involve effects on either ATM mRNA expression or pro-
tein stability. To address the former possibility, we next
investigated whether ΔNp63α overexpression affected
ATM steady-state mRNA levels. Basal ATM transcription
was detectable in cells transfected with control vector
(Figure 4A). However, ΔNp63α transfection stimulated a
6-fold increase in steady-state ATM mRNA levels,
approximately twice the level of stimulation by the estab-
lished ATM regulator, E2F-1 [21]. We also show that
endogenous ΔNp63α binds the ATM promoter in vivo
(Figure 4B). In contrast, TAp63α function was strongly
attenuated compared to that of ΔNp63α, and p53 expres-
sion strongly inhibited ATM mRNA expression. Similar
data were obtained when the effects of p63 overexpres-
sion on an exogenous ATM promoter were measured
(Figure 4C). Basal ATM reporter activity was detectable
in cells transfected with a control vector. However, this
was stimulated approximately 1.8-fold following cotrans-
fection with ΔNp63 α and γ variants, 1.3-fold by the ATM
regulator E2F-1, but not stimulated by TAp63α or p53
coexpression. These data indicate that p63-dependent
changes in steady-state ATM mRNA expression are pri-
marily due to promoter regulation, and not due to effects
on ATM mRNA stability. Titration of p63 or E2F-1
revealed that the ATM promoter was similarly sensitive
to ΔNp63 isoforms and E2F-1 (Figure 4D), although max-
imal levels of ΔNp63-stimulated ATM promoter activity
were reproducibly higher than E2F-1-stimulated activity.
Relative levels of ΔNp63α and E2F-1 bound to reporter
DNA were similar (Figures 4E, F). Thus, differences in
ATM promoter stimulation are not likely to reflect differ-
ences in p63 and E2F-1 expression in this system. In sum-
mary, (i) ΔNp63α binds the ATM promoter and
stimulates ATM transcription, and (ii) this in part main-
tains ATM-dependent phosphorylation of p53.
The CCAAT element mediates ΔNp63α-dependent 
stimulation of the ATM promoter
The DNA binding (DB) domain of p63 is 65% homolo-
gous to that of p53, and p63 variants can recognise p53
response elements (REs) [2,22]. Thus, ΔNp63α-mediated
ATM transcription could either involve direct binding to
the ATM promoter via the DB domain, or indirect bind-
ing via an unidentified cofactor. Previous analysis of the
ATM promoter failed to identify a p53 RE, although bind-
ing sites for several other transcription factors were iden-
tified [23]. We therefore used a series of ATM reporter
constructs containing point mutations at putative REs to
identify sequences required for basal and ΔNp63α-stimu-
lated ATM transcription (see Figure 5A) [23]. Basal ATM
reporter activity is absent in mutant ATM reporter con-
structs lacking either the Ire2 or Fse REs, which were pre-
viously found to control ATM transcription in cycling
normal human fibroblast and lymphoblastoid cells [23].
ΔNp63α-induced ATM reporter activity was specifically
attenuated by mutation of the NF-1 RE, encoded by the
AGCCAAT sequence (Figure 5B), and containing a
CCAAT element. Mutation of the CCAAT element also
blocked E2F-1-mediated ATM promoter stimulation
(Figure 5B). This was unexpected as deletion mutagenesis
had previously located the E2F-1 target region to between
-436 and -392 (Figure 5A 10379-10423), containing two
putative E2F-1 REs. However, as this deletion also
removes the CCAAT element at -435 - -429 (10380-
Craig et al. Molecular Cancer 2010, 9:195
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Page 5 of 1310386), we reinterpret the original data to indicate that
E2F-1 regulates ATM transcription through interaction
with the same CCAAT element as ΔNp63α. In support of
this, we found that ΔNp63α and E2F-1 do not synergisti-
cally activate the ATM promoter, but instead have addi-
tive effects (Figure 5C).
Cooperation of distinct functional domains controls 
ΔNp63α function
Causative p63 germline mutations have been identified in
distinct human developmental disorders characterised by
limb deformities and facial clefting. To identify ΔNp63α
functional domain(s) involved in ATM regulation, we
Figure 3 ΔNp63 isotypes stimulate ATM-dependent phosphorylation. (A) p63 controls clonogenic cell growth in tumour cells. H1299 cells were 
transfected with 1 μg p63 plasmids TAα, TAγ, ΔNα, or ΔNγ, or empty vector control, colonies were giemsa stained after 14 days selection and counted. 
(B) ΔNp63 isoforms stimulate p53 Serine-15 phosphorylation. H1299 cells were cotransfected with 0.2 μg p53 and 0.5 - 1 μg p63 variant as indicated 
and harvested after 48hrs. Lysates were blotted for the indicated proteins. (C) TAp63 isoforms induce p21WAF1 protein expression. H1299 cells were 
transfected with 1 μg p53, E2F-1, p63 isoforms TAα, TAγ, ΔNα, or ΔNγ, or empty vector control, and harvested after 48 hours. Lysates were immunob-
lotted for the indicated proteins.
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Figure 4 ΔNp63 isotypes bind the ATM promoter in vivo and stimulate ATM transcription. (A) The indicated genes (1 μg) were transfected into 
Saos2 cells. Cells were harvested after 24 hrs, total RNA was isolated and analyzed for ATM gene expression by real time RT-PCR. ATM gene expression 
was normalized to β-actin, and the data is represented as fold-change over empty vector control. (B) ΔNp63α and E2F-1 bind the endogenous ATM 
promoter in vivo. Protein-DNA complexes in cycling HaCat cells were crosslinked and analysed by chromatin immunoprecipitation using anti-p63 or 
anti-E2F-1 antibodies or no antibody control. Crosslinks were reversed and purified DNA was quantified by real-time PCR using ATM primers. Relative 
amounts of INPUT DNA were 1/10 for ATM. (C) ΔNp63 isoforms stimulate ATM -LUC reporter activity. H1299 were co-transfected with 1 μg ATM-LUC, 
0.2 μg pRL-CMV plasmids, and 1 μg empty pCDNA3.1, p53, E2F1 plasmids, or p63 plasmids expressing ΔNα, ΔNγ, TAα or TAγ isoforms. Cells were har-
vested after 24 hrs and luciferase activity was analysed by Dual-Luciferase reporter assay kit (Promega). Data is normalised to the empty vector control. 
(D) The ATM promoter is more sensitive to E2F-1 than ΔNp63α. H1299 cells were transfected with 10ng, 100ng or 1000ng E2F-1 or p63 expression 
plasmids, and reporter plasmids, and harvested as described above. Specific ATM reporter activity was determined as described previously (C). (E)-(F) 
ΔNp63α and E2F-1 bind an exogenous ATM promoter in vivo. H1299 cells were transfected the ATM-LUC reporter plasmid, and co-transfected with 
ΔNp63α (E) or E2F-1 (F) expression plasmids Protein-DNA complexes were crosslinked after 24 hrs, and ChIP analysis was done using anti-p63 or anti-
E2F-1 antibodies. Crosslinks were reversed and purified DNA was quantified by real-time PCR using ATM primers. Relative amounts of INPUT DNA were 
1/100.
 
 
 
 
 
C 
A 
-6
-4
-2
0
2
4
6
8
Ne
ga
tiv
e
Em
pt
y
p5
3
E2
F-
1
Np
63
TA
p6
3
Ne
ga
tiv
e
Em
pt
y
p5
3
E2
F-
1
Np
63
TA
p6
3
Ne
ga
tiv
e
Em
pt
y
p5
3
E2
F-
1
NNp
63
TA
p6
3
R
el
at
iv
e 
AT
M
 m
R
N
A 
  l
ev
el
s 
p63 expression increases ATM mRNA levels 
p63 binds the ATM promoter 
0 
50 
100
150
200
250
INPUT NoAb p63 E2F-1 
Bo
un
d 
AT
M
 p
ro
m
o
te
r-a
rb
itr
ar
y 
u
n
its
 
Dose-dependent stimulation of the ATM reporter
0 
0.5 
1 
1.5 
2 
2.5 
3 Normalised to empty vector 
basicEmpty
E2F-1 N TA
Dose-dependent stimulation of the ATM reporter 
0 
0.5 
1 
1.5 
2 
2.5 
3 
 
 
 
 
 
 
 
 
 
Lu
ci
fe
ra
se
 a
ct
iv
ity
 
pG
L3
-
a
si
c 
Em
pt
y 
N TA
p63 controls ATM reporter activity 
0 
0.5 
1 
1.5 
2 
2.5 
pG
L3
-
ba
sic
 
e
m
pt
y p53 E2F-1 N  N  TA  TA  
 
 
 
 
 
 
 
 
 
Lu
ci
fe
ra
se
 a
ct
iv
ity
 
0
5
10
15
20
25
INPUT NoAb p63
NT
pGL3-basic
ATM-LUC
Np63  binds the ATM promotor in vivo 
B 
0
2
4
6
8
10
12
INPUT NoAb E2F-1
NT
pGL3-basic
ATM-LUC
E2F-1 binds the ATM promotor in vivo 
D 
E 
F 
Craig et al. Molecular Cancer 2010, 9:195
http://www.molecular-cancer.com/content/9/1/195
Page 7 of 13
Figure 5 The CCAAT element mediates ΔNp63α- and E2F-1-dependent stimulation of the ATM promoter. (A) Schematic representation of the 
human ATM promoter organisation (Genebank U82828), showing the position of putative response elements which are mutated in this study. (B) The 
CCAAT sequence mediates ΔNp63α and E2F-1 stimulated ATM transcription. H1299 cells were co-transfected with 1 μg ΔNp63α respective with 1 μg 
E2F-1, 1 μg ATM-LUC (wt or CCAAT mutant) and 0.2 μg pRL-CMV control plasmids, then lysed and processed after 24 hrs. Specific ATM-LUC activity 
was determined as described in Figure 4 throughout, and data is normalised to wild-type reporter activity. (C) ΔNp63α and E2F-1 have additive effects 
on ATM promoter stimulation. H1299 cells were transfected with 0.5 μg ΔNp63α, E2F-1 or 0.5 μg each plasmid along with 1 μg ATM-Luc (wt or mutant) 
and 0.2 μg pRL-CMV control plasmids, and cells were harvested and processed after 24 hrs. Total DNA was balanced with empty pCDNA3.1 vector.
B
A
10300          10400          10500           10600          10700          10800           10900
EXON 1
Ir
e
(1
)
G
C
F
N
F
1
C
re
S
p
1
(1
)
S
p
1
(2
)
Ir
e
(2
)
X
re
E
ts
M
yb
F
seIr
e
(1
)
G
C
F
N
F
1
C
re
S
p
1
(1
)
S
p
1
(2
)
Ir
e
(2
)
X
re
E
ts
M
yb
F
se
ATM promoter
C
p63-dependent ATM promoter stimulation requires an NF-1 site
0
0.2
0.4
0.6
0.8
1
1.2
pGL3-basic ATM-LUC WT ATM-LUC NF-1 pGL3-basic ATM-LUC WT ATM-LUC NF-1 pGL3-basic ATM-LUC WT ATM-LUC NF-1
Empty p63N E2F-1
Lu
ci
fe
ra
se
 a
ct
iv
ity
Additive effect of p63 and E2F-1 on ATM promoter
0
0.5
1
1.5
2
2.5
3
empty E2F1 Np63 Np63/E2F1
Lu
ci
fe
ra
se
 a
ct
iv
ity
Craig et al. Molecular Cancer 2010, 9:195
http://www.molecular-cancer.com/content/9/1/195
Page 8 of 13assayed the effects of both disease-related ΔNp63α point
mutants (Table 1) and synthetic deletions on ATM pro-
moter stimulation (illustrated in Figure 6AII).
TA2 transactivation domain
The TA2 transactivation domain comprises 14 amino
acids unique to the ΔNp63 isoforms and 12 amino acids
common to both TA and ΔN isoforms (Figure 6AI). Dele-
tion of the ΔN-specific 14 amino acids blocked ΔNp63α-
dependent ATM promoter stimulation (Figure 6B, CUT-
1), and replacing the ΔN-specific 14 amino acids with the
equivalent TA-specific residues failed to restore ATM
transcriptional activity (Figure 6B, TANp63α). Thus, the
ΔNp63-specific nucleotides within TA2 are critical for
ATM transcriptional control. However, the acro-der-
mato-ungual-lacrimal-tooth (ADULT) syndrome N6 H
mutation within this sequence did not affect ΔNp63α
activity, suggesting that the clinical phenotypes of this
disease are not mediated by loss of ATM function. In
contrast, deletion of the 12 common TA2 domain resi-
dues reduced ATM promoter stimulation by roughly 50%
(Figure 6B, CUT-2). The limb-mammary syndrome
(LMS)-related G76W mutant located within this
sequence had a similarly reduced ATM transactivation
potential, indicating that Glycine-76 makes a critical con-
tribution to ΔN-specific p63 transcriptional activity (Fig-
ure 6B, G76W), and that reduced TA2-dependent
transcription may be a causative factor in this disease.
DB domain
Several p63 DB domain mutants associated with Ectro-
dactyly-ectodermal dysplasia-cleft syndrome (EEC) syn-
drome are homologous to p53 tumour-associated
hotpoint mutants that disrupt p53 DNA-binding func-
tion. The ΔNp63α R204W (equivalent to p53 R175) and
R279 H (equivalent to p53 R248H) mutants had a
reduced ability to stimulate the ATM promoter (Figure
6C), implicating the DB domain in ΔNp63α-mediated
ATM transcription. Interestingly, the ADULT syndrome
R298Q DNA-binding domain mutant, previously
reported to enhance ΔNp63γ TA2-dependent transcrip-
tion through an intramolecular mechanism [3], stimu-
lated the ATM promoter 1.3-fold relative to wild-type
ΔNp63α (Figure 6C). We showed that hyperactivity of
this mutant was mediated solely by the ATM promoter
CCAAT element (Figure 6D) and that it was ablated in a
double site R298Q/R279 H mutant (Figure 6C).
SAM domain
Although both α and γ ΔNp63 isotypes stimulated an
exogenous ATM promoter to similar levels, only ΔNp63α
effectively induced intrinsic ATM kinase activity, suggest-
ing that C-terminal p63 domains specific to the alpha-
isotype are essential to regulate the endogenous ATM
promoter. Alpha splice variants of both p63 and p73 con-
tain a SAM protein-protein interaction domain that may
be important for cofactor recruitment. The NMR struc-
ture of the p63 SAM domain revealed a 5 alpha helix bun-
dle with a hydrophobic core [24], which is disrupted by
ankyloblepharon-ectodermal dysplasia-clefting (AEC)-
specific point mutations [25]. Ectopic expression of
ΔNp63α AEC mutants C522W or I537T had an attenu-
ated ability to stimulate the ATM promoter (Figure 6E),
and both mutations blocked ΔNp63α-dependent stimula-
tion of p53 Serine-15 phosphorylation (Figure 6F).
These data indicate critical roles for the TA2, DB and
SAM domains in regulating ΔNp63α-dependent ATM
transcription, and suggest that reduced ATM function
may be a factor in the clinical manifestation of specific
p63 germline disorders [25].
Discussion
p53 is the primary mediator responsible for removing
DNA damaged epidermal cells [26], and p53 phosphory-
lation at the CK2-site is required to suppress UV-induced
skin cancer development in mice [13]. We previously
Table 1: Germline p63 point mutations
Point Mutation Domain Syndrome
N6H TA2 ADULT
G76W TA2 LMS
R204W DBD "175" EEC
R279H DBD "248" EEC
R298Q DBD (TTA2*) ADULT
C522W SAM AEC
I537T SAM AEC
The functional domain containing each mutation site, and the developmental disorder associated with each mutant is indicated. Numbers 
in inverted commas ("") refer to the site of homologous hotspot mutations in p53, and TA2* refers to the activation of TA2 function by the 
R298Q mutation. ADULT, acro-dermato-ungual-lacrimal-tooth; LMS, limb-mammary syndrome; EEC, ectrodactyly-ectodermal dysplasia-
clefting; AEC, ankyloblepharon-ectodermal dysplasia-clefting.
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Figure 6 ΔNp63α mutants alter ATM transcription and ATM-dependent phosphorylation. (A) (I) Sequence alignment of the amino-termini of 
TAp63 and ΔNp63, indicating conserved residues. (II) Domain structure of ΔNp63α, indicating sites of point mutations used in this study, and an ex-
pansion of the TA2 transactivation domain showing ΔN-specific residues deleted in the CUT-1 mutant, and residues common to both ΔN and TA iso-
forms that are deleted in the CUT-2 mutant. (B) Effect of TA2 transactivation domain mutation on ΔNp63α-stimulated ATM promoter activity. H1299 
cells were co-transfected with 1 μg either wild-type or the indicated mutant ΔNp63α plasmids, and 1 μg ATM-LUC and 0.2 μg pRL-CMV reporter plas-
mids. Cells were lysed and processed after 24 hrs, and specific ATM reporter activity was determined as in Figure 4 and is normalised to wild-type 
values. (C) DNA binding domain mutants have opposing effects on ΔNp63α-stimulated ATM promoter activity. H1299 cells were co-transfected with 
1 μg either wild-type or the indicated mutant ΔNp63α plasmids, and 1 μg ATM-LUC and 0.2 μg pRL-CMV reporter plasmids. Cells were lysed and pro-
cessed after 24 hrs, and specific ATM reporter activity was determined as in Figure 4 and is normalised to wild-type values. (D) Mutation of the CCAAT 
sequence blocks R298Q ΔNp63α-mediated stimulation of ATM transcription. H1299 cells were co-transfected with 1 μg R298Q ΔNp63α, 1 μg ATM-
Luc (wt or mutant) and 0.2 μg pRL-CMV control plasmids, then lysed and processed after 24 hrs. Specific ATM reporter activity was determined as in 
Figure 4 and is normalised to wild-type values. (E) SAM domain mutants attenuate ΔNp63α-stimulated ATM promoter activity. H1299 cells were co-
transfected with 1 μg either wild-type or the indicated mutant ΔNp63α plasmids, and 1 μg ATM-LUC and 0.2 μg pRL-CMV reporter plasmids. Cells 
were lysed and processed after 24 hrs, and specific ATM reporter activity was determined as in Figure 4 and is normalised to wild-type values. (F) Hay-
Wells/AEC syndrome-associated ΔNp63α mutants inhibit ATM-dependent p53 Serine-15 phosphorylation. H1299 cells were cotransfected with 0.2 
μg p53 and 1 μg of either wild-type or mutant ΔNp63α as indicated, and harvested after 48hrs. Lysates were blotted with phosphoSerine-15 p53, total 
p53 and p63 protein.
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Page 10 of 13reported the striking confinement of UV-induced p53
phosphorylation at the key damage-response CK2 and
ATM sites to ΔNp63α-positive basal skin cells, despite
substantial p53 stabilization throughout the epidermis
[27]. We next aimed to identify novel factors that control
damage-induced p53 phosphorylation in a keratinocyte
model system, and discovered that the epithelial stem cell
marker ΔNp63α is a novel ATM regulator that controls
p53 Serine-15 phosphorylation through transcription of
the ATM kinase. Loss of ΔNp63α by RNAi or differentia-
tion reduced ATM-dependent phosphorylation and con-
versely, ΔNp63α overexpression stimulated ATM
signaling. A recent genome-wide screen reporting that
ATM expression is reduced by 30-60% in p63 siRNA-
treated epithelial cell lines supports our finding [28].
Post-translational activation of the ATM kinase by ion-
izing radiation, oxidative stress, chemotherapeutic drugs
[15] and UV radiation is well-established [29]. However,
ATM transcriptional regulation has been shown to occur
both in vitro and in vivo [30]. E2F-1 stimulation of ATM
transcription [21] has been implicated in oncogene-
mediated p53 activation [31]. In contrast, epidermal
growth factor sensitizes cells to ionizing radiation
through Sp1-mediated repression of ATM transcription
[32]. We have shown that p63 ΔN-isotypes are novel pos-
itive regulators of ATM transcription that interact with
the promoter CCAAT sequence. p63-dependent gene
regulation has been reported to occur through interac-
tion of the DB domain with a p53 RE [22]. However, the
lack of similarity of the CCAAT sequence to classical p53
REs suggests that p63 interaction with a CCAAT element
is indirect, and requires a CCAAT-binding mediator. We
show that the E2F-1 regulates ATM transcription
through the same CCAAT sequence, not a canonical E2F-
1 response element, suggesting that a CCAAT-binding
cofactor integrates activation signals from diverse ATM
transcriptional regulators. CCAAT-binding proteins
include NF-1/CTF [33], NF-Y [34] and C/EBP [35]. NF-Y
can mediate ΔNp63α-dependent transcription in human
keratinocytes [10,36], p53-dependent repression of cell
cycle genes [37], and transcriptional activation by p53
gain-of-function mutants [38]. However, we found that
coexpression of the NF-YA isoform inhibits ΔNp63α
stimulation of the ATM reporter (data not shown), pre-
sumably by displacing the unidentified ΔNp63α coactiva-
tor from the ATM promoter CCAAT element. Ongoing
studies aim to further delineate the mechanism of
ΔNp63α-mediated ATM transcriptional control by iden-
tifying ΔNp63α binding partners in epithelial cells.
Based on our findings so far, cooperation of three dis-
tinct functional domains is required to mediate p63-
dependent ATM transcription. We found that p63 ΔN-
isotypes transcriptionally activate the ATM gene,
whereas TA-isotypes do not, highlighting an essential
role for the TA2 transactivation domain in mediating
ΔNp63α function. Future studies will aim to determine
which cofactors are recruited to this region, and whether
their access is controlled by TA2 domain post-transla-
tional modification, similar to the p53 model [39]. There
was also a requirement for an intact p63 DB domain,
despite the absence of a canonical p53 RE in the ATM
promoter. However, in addition to providing a surface for
the sequence-specific binding of DNA, the p53 DB
domain modulates p53 function by providing a contact
interface for regulatory proteins such as ASPP1, Mdm2,
and DAPK superfamily kinases [40,41], and the high
degree of conservation of the p63 DB domain suggests
that a similar interface exists on p63. Finally, the p63
SAM domain forms a binding site for NF-Y [36], and
SAM domain disease-associated mutants have decreased
transcriptional repressor and activator function [7,42].
We found that AEC point mutations within the SAM
domain [25] inhibited ΔNp63α-stimulated ATM tran-
scription and ATM-dependent p53 phosphorylation,
indicating that this domain may be essential for cofactor
recruitment by the ΔNp63α. Interestingly, the AEC clini-
cal phenotype predominantly involves skin defects with-
out associated limb abnormalities [42], consistent with a
skin-specific role for ΔNp63α-ATM-p53 signaling in
mediating normal ectodermal development. Therefore,
the coordinated assembly of several cofactors may be
required for fully functional p63 transcriptional machin-
ery.
According to our model, elevated ΔNp63α-dependent
ATM transcription primes p53 leading to damage-sensi-
tivity in epithelial stem cells. Loss of p63-ATM-p53 path-
way function will compromise epithelial stem cell
function and promote premature ageing or skin carcino-
genesis. Interestingly, transgenic mice with a specific
p63-deficiency in the epithelium show increased senes-
cence and an accelerated ageing phenotype [43].
Although transgenic mice lacking the Serine-18 (equiva-
lent to human Serine-15) ATM phosphorylation site are
not cancer-prone [44], it is now important to determine
whether mutation at p53 Serine-18 enhances sensitivity
to UV-induced skin tumorigenesis, similar to mutation of
the CK2-site. Interestingly, p53S18A/S23A (ATM-/
CHK2-sites) double mutant mice develop a spectrum of
spontaneous tumours distinct from p53S23A and p53-
null mice, and show accelerated skin ageing phenotypes
when crossed into a repair-deficient background [45].
Further, activation of the ATM-CHK2 pathway during
early tumorigenesis has been reported to provide a selec-
tive pressure for p53 mutation [46]. The discovery that
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activation and repression by ΔNp63α [17], and that
ATM-dependent phosphorylation mediates ΔNp63α deg-
radation [47] suggests that activity of the damage-
response ΔNp63α-ATM-p53 pathway is finely modulated
by complex feedback mechanisms. Further dissection of
this pathway should provide molecular targets for com-
bating cancer and ageing.
Materials and methods
Cell Treatments
HaCat and Saos-2 cells were maintained in DMEM
supplemented with 10% FCS. H1299 cells were main-
tained in RPMI supplemented with 10% FCS. p63
expression plasmids were obtained from Dr Karin
Nylander, and transient transfections were done using
lipofectamine LF2000 (Invitrogen). Ambion
silencerTM siRNA oligonucleotides were used to block
ATM expression: sense 5'-gccagcaaauucuagugcctt -3'
antisense: 5'-ggcacuagaauuugcuggctc-3'. Transfection of
HaCaT cells with 200 pMol ATM siRNA used the
siPORTTM NeoFXTM transfection reagent. Dharmacon
ON-TARGETplus SMARTpool p63 siRNA was used to
knockdown p63 expression using the DharmaFECT 1
transfection reagent. ON-TARGETplus siCONTROL
Non-targeting pool was used for control transfections.
pSUPER-p63si stable transfections were done as previ-
ously described [17].
Site-directed mutagenesis
ΔNp63α site-directed mutagenesis used the QuikChange®
Site-Directed Mutagenesis Kit (Stratagene) and the fol-
lowing primers:
N6H-For 5'-TTGTGAAATGGTGCCCTAACCATGA
GCTGAGCCGTG-3'; N6H-Rev 5'-AATTGAGTCTG-
GGCATTGTGTTCCAGGTACAAC-3'; G76W-For 5'-
GTACACGAACCTGTGGCTCCTGAACAGCATGG-3';
G76W-Rev 5'-CCATGCTGTTCAGGAGCCACAGGT-
TCGTGTAC-3'; R204W-For 5'-TTGTGAAATGGTGC-
CCTAACCATGAGCTGAGCCGTG-3'; R204W-Rev 5'-
CACGGCTCAGCTCATGGTTAGGGCACCATTTCA-
CAA-3'; R279H-For 5'-GCTGCGTCGGAGGAAT-
GAACCATCGTCCAATTTTAATC-3'; R279H-Rev 5'-
GATTAAAATTGGACGATGGTTCATTCCTCCGACG
CAGC-3'; R298Q-For 5'-CAAGTCCTGGGCCAACGC
TGCTTTG-3'; R298Q-Rev 5'-CAAAGCAGCGTTGGC-
CCAGGACTTG-3'; C522W-For 5'-GTTGGGCTGT-
TCATCATGGCTGGACTATTTCACGAC-3' C522W-
Rev 5'-GTCGTGAAATAGTCCAGCCATGATGAACA
GCCCAAC-3'; I537T-For 5'-GACCACCATCTATCA-
GACTGAGCATTACTCCATG-3'; I537T-Rev 5'-CATG-
GAGTAATGCTCAGTCTGATAGATGGTGGTC-3';
CUT1-For 5'-GGCCTCGAGCCACAGTACACGAACC
T-3'; CUT1-Rev 5'-ACCTCTAGATCATTCTCCTTCC-
3'; CUT2-For1 5'-GGCCTCGAGGACCAGCAGAT-
TCAGAAC-3'; CUT2-For2 5'-GGCCTCGAGTTGTA
CCTGGAAAACAATGCCCAGACTCAATTTAGTGG-
GACCAGCAGATTCAGAAC-3'; CUT2-Rev 5'-ACCTC
TAGATCATTCTCCTTCC-3'; TAN-For 5'-GGCCTC
GAGTGTATCCGCATGCAAGACTCAGACCTCAGT
GACCCCATGTGGCCACAGTACACGAACCT-3';
TAN-Rev 5'-ACCTCTAGATCATTCTCCTTCC-3'.
Immunoblotting
Immunoblotting was done essentially as described previ-
ously [40]. p53 protein was detected using DO-1 and DO-
12 anti-p53 antibodies, specific p53 Serine-15 phospho-
rylation was detected using p53 phosphoSerine-15 anti-
bodies (New England Biolabs), and all p63 isoforms were
detected using the 4A4 antibody (Abcam). Anti-ATM
(5C2, GeneTex) and anti-ATM phosphoSerine-1981
(clone 10H11.E12, Upstate) antibodies were used.
Reporter Assays
Wild-type and mutant human ATMpLUC reporter plas-
mids [23] and the Arf exon1 βpLUC reporter plasmid [48]
were previously described. 1 μg of expression plasmid, 1
μg of reporter plasmid and 0.2 μg of pRL-CMV plasmid
were cotransfected into H1299 cells using lipofectamine,
and cells were harvested after 24 hours. Reporter activity
was determined using the Dual-Luciferase reporter assay
kit (Promega).
Colony Formation Assays
H1299 cells were transfected with 1 μg of p63 expression
plasmid, and selected using 1 μg/ml geneticin (Invitro-
gen). After 14 days, colonies were stained with Giemsa
and counted.
Real-Time PCR
Total mRNA was extracted using the Qiagen RNeasy Kit,
and 40ng samples were analysed by real-time RT-PCR
using Quantitect® SYBR® Green detection. RT-PCR condi-
tions were: 50°C for 30 min, 95°C, 15 min, and 44 cycles
of 95°C for 15 sec, 55°C for 30 sec, 72°C for 45 sec. Melt-
ing curves were recorded from 60°C to 95°C. Primers
were: p63-For 5'-GGAAAACAATGCCCAGACTC-3';
p63-Rev 5'-GCTGTTCCCCTCTACTCGAA-3'; ATM-
For 5'-CCAGGCAGGAATCATTCAG-3'; ATM-Rev 5'-
CAATCCTTTTAAATAGACGGAAAGAA-3'; Actin-For
5'-CTACGTCGCCCTGGACTTCGAGC-3'; Actin-Rev
5'-GATGGAGCCGCCGATCCACACGG-3'.
Chromatin Immunoprecipitation Assays
4 μg of 4A4 (Abcam) antibody was used to immunopre-
cipitate p63-DNA complexes, and 4 μg of KH95 antibody
(Santa Cruz) was used to immunoprecipitate E2F-1-DNA
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time PCR, and input DNA dilutions are indicated in fig-
ure legends. Primers used were:
ATM For 5'-AAAACCACAGCAGGAACCAC-3';
ATM Rev 5'-TCCAAGTCTGAGGACGGAAG-3'; GAP
DH For 5'-AAAAGCGGGGAGAAAGTAGG-3'; GAP
DH Rev 5'-CTAGCCTCCCGGGTTTCTCT-3'. The pro-
gramme used was: 95°C, 15 min, then 40 cycles of 95°C,
15 sec, 56°C, 30 sec, 72°C, 30 sec, and product melting
curve was read from 60°C to 95°C at 1°C intervals.
Reporter ChIP
10 cm culture dish of H1299 cells were transiently trans-
fected with 6.7 μg ΔNp63α or HA-E2F-1 expression plas-
mids 1.67 μg pGL3-basic or ATMpLUC and 1.67 μg pRL-
CMV. Cells were crosslinked after 24 hrs and processed
as outlined above.
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